摘要
目的探讨与研究抗肝纤丸联合替诺福韦治疗乙肝肝纤维化的疗效,明确其应用价值。方法选取160例慢性乙型肝炎肝纤维化患者采用数字表法随机分为观察组和对照组,每组各80例。对照组患者服用替诺福韦进行治疗,治疗周期为48周;观察组在对照组的基础上采用替诺福韦加抗肝纤丸进行联合治疗,治疗周期为48周。观察并比较两组临床效果。结果在治疗后,观察组患者的ALT、TBIL、AST肝功能指标和LN、ⅣC、HA、PⅢP肝纤维化指标均低于对照组,差异具有统计学意义(P<0.05)。结论抗肝纤丸对改善肝功能、抑制肝纤维化有明显的积极意义,替诺福韦与其联合治疗乙肝肝纤维化治疗效果显著提高,值得大力推广。
Objective To investigate the efficacy of anti-liver fiber pills combined with tenofovir in the treatment of hepatitis B liver fibrosis, and to clarify its application value. Methods One hundred and sixty patients with chronic hepatitis B liver fibrosis were randomly divided into observation group and control group by digital table method, 80 cases in each group. The patients in the control group were treated with tenofovir for a period of 48 weeks. The observation group was treated with tenofovir plus anti-liver pills on the basis of the control group for a treatment period of 48 weeks. The clinical effects of the two groups were observed and compared. Results After treatment, the ALT, TBIL, AST liver function indexes and liver fibrosis indexes of LN, IVC, HA and PIIIP were lower in the observation group than in the control group, and the difference was statistically significant (P<0.05). Conclusion Kangganxian Pill has obvious positive effect on improving liver function and inhibiting liver fibrosis. Tenofovir and its combination therapy for hepatitis B liver fibrosis have a significant improvement effect, which is worthy of promotion.
作者
沈科书
张诗琪
SHEN Ke-shu;ZHANG Shi-qi(Jilin Liver and Gallbladder Disease Hospital, Changchun, Jilin 130062;Basic Medical College of Tianjin MedicalUniversity, Tianjin 300070)
出处
《智慧健康》
2019年第20期100-101,共2页
Smart Healthcare
关键词
乙肝肝纤维化
替诺福韦
抗肝纤丸
联合治疗
Hepatitis B liver fibrosis
Tenofovir
Anti-liver fiber pills
Combination therapy
